Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

← Ovarian Epithelial Carcinoma

Ovarian Epithelial Carcinoma: treatment map

Standard care plus compounds studied in the literature, organized by clinical readiness.

Educational only. This is not medical advice and not a recommendation. Confirm anything here with your oncology team.

Treatment map: Ovarian Epithelial Carcinoma

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

133
Interventions
0
Standard of care
7
Tested in people
6
Lab / animal
112
Named in lit.
9
Classes
Standard of care (0) Guideline option (8) Tested in people (7) Lab / animal only (6) Named in the literature (112)

Tested in people, by trial phase: Phase III ×1 · Phase II ×2 · phase not reported ×4

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
—
—
1
—
21
Radiotherapy
—
—
—
—
5
Chemotherapy
—
4
5
2
26
Targeted therapy
—
3
—
1
10
Immunotherapy
—
—
—
—
10
Hormonal therapy
—
—
—
2
5
Repurposed drugs
—
—
—
—
7
Supplements & natural agents
—
—
—
—
1
Other
—
1
1
1
27

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (8)
Chemotherapy
carboplatin
FDA-approved for this cancer.
—Guideline option
cisplatin
FDA-approved for this cancer.
—Guideline option
doxorubicin
FDA-approved for this cancer.
—Guideline option
Gemcitabine
FDA-approved for this cancer.
—Guideline option
Targeted therapy
bevacizumab
FDA-approved for this cancer.
—Guideline option
rucaparib
FDA-approved for this cancer.
—Guideline option
olaparib
FDA-approved for this cancer.
—Guideline option
Other
Relacorilant
FDA-approved for this cancer.
—Guideline option
Investigational & adjunct compounds — detail (125)
Phase III trial (1)
Tumor Treating Fields
Phase II trial (2)
ifosfamide plus etoposidepaclitaxel + epirubicin + cisplatin
Tested in people (4)
CA125cisplatinum-cyclophosphamidemelphalanpaclitaxel plus poldine
Named in the literature
primary cytoreductive surgeryneoadjuvant chemotherapyPARP inhibitorssecondary cytoreductive surgeryendocrine therapytaxane-platinum combinationsurgerylymphadenectomy?gamma delta T cellsmifepristonetaxollobaplatinaspirincyclophosphamide and cisplatinoral metronomic chemotherapyintraperitoneal chemotherapyCYH33anti-PD-1humanized PDX modelcarboplatin/paclitaxelpegylated liposomal doxorubicinimatinibchemotherapyradiotherapyhormone therapycheckpoint inhibitorsanlotinibradiation therapyhyperspectral imagingplatinum-based chemotherapytargeted therapiesheat shock-conditioned OEC lysatesdendritic-cell-based immunotherapyPGC1αdocetaxel and carboplatinpaclitaxel and cisplatinp62/SQSTM1miR-152c-FosoxamflatinAMHR2-CDREG4miR-106bmiR-490-3PRhoCTGF-β1 and VEGFBIBF1120 and SB431542oseltamivir phosphateoff-labelSnail and Slug shRNAlysophosphatidic acidpaclitaxel, cisplatin, gemcitabine, 5-fluorouracilRhoA siRNA and Wnt-5a siRNATCRγ9δ2(OT3)-FcresistinRhoC siRNALovastatinoff-labelNesfatin-1GhrelinCDR3δ-grafted γ9δ2T cellsHE4Lewis y antigenT-oligosluteinizing hormonepsammoma bodiesEGFRGST epitope fusion proteinsOT10 peptideAdipoR1platinum-based systemic chemotherapyMICAPON1Essiacsurgical en bloc removalradiotherapy and chemotherapyplatinum-based combination chemotherapyplatinum-based combination chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteriessuraminHMOCC-1HIFUMICA-reactive Vdelta1 gammadelta T cellswhole-abdominal radiotherapycisplatinumgenisteinadriamycinPc 4FSHmembrane vesiclestelomerase determinationuniversal grading systemc-fms ribozymealpha2beta1-integrinLHRH agoniststumor necrosis factor-alphaLupron-SRPhotofrin IIHexametilmelanineabdominopelvic irradiationinterleukin 2lymphokine-activated killer cellsCA 125adriamycin and cis-platinummelphalan and levamisolepaclitaxel liposome + carboplatinshort-course hypofractionated radiation therapy5-fluorouracilcisplatin, etoposide, bleomycincisplatinum, cytoxan, adriamycincarboplatin and etoposideOxaliplatinsiCXCR4CD44v6-O-MWNTS
Lab / animal only
paclitaxeloff-labelliposomal doxorubicinanastrozoleoff-labelNiraparib †RxTamoxifenoff-labelTopotecanoff-label

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.